Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: A report from the Berlin-Frankfurt-Muenster group

Journal of Clinical Oncology

Volumn 27, Issue 20, 2009, Pages 3363-3369

  Burkhardt, Birgit ^a   Reiter, Alfred ^a   Landmann, Eva ^a   Lang, Peter ^a   Lassay, Lisa ^a   Dickerhoff, Roswitha ^a   Lakomek, Max ^a   Henze, Günter ^a   Von Stackelberg, Arend ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; ETOPOSIDE; FLUDARABINE; IDARUBICIN; IFOSFAMIDE; MELPHALAN; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; THIOTEPA; VINCRISTINE; VINDESINE; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADOLESCENT DISEASE; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; COLON ADENOCARCINOMA; DISEASE COURSE; HUMAN; LYMPHOBLASTOMA; MAINTENANCE THERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; SCHOOL CHILD; UNSPECIFIED SIDE EFFECT; WHOLE BODY RADIATION; ADULT; ALLOTRANSPLANTATION; ANALYSIS OF VARIANCE; FEMALE; GERMANY; KAPLAN MEIER METHOD; MALE; METHODOLOGY; MULTICENTER STUDY; RECURRENT DISEASE; STEM CELL TRANSPLANTATION; SWITZERLAND; TREATMENT OUTCOME;

ADOLESCENT; ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; DISEASE PROGRESSION; FEMALE; GERMANY; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MULTICENTER STUDIES AS TOPIC; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; RECURRENCE; STEM CELL TRANSPLANTATION; SWITZERLAND; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 70249135305     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.19.3367     Document Type: Article

References (35)

1. Patte C, Kalifa C, Flamant F, et al: Results of the LMT81 protocol, a modified LSA2L2 protocol with high dose methotrexate, on 84 children with non-B-cell (lymphoblastic) lymphoma. Med Pediatr Oncol 20:105-113, 1992
2. Eden OB, Hann I, Imeson J, et al: Treatment of advanced stage T cell lymphoblastic lymphoma: Results of the United Kingdom Children's Cancer Study Group (UKCCSG) protocol 8503. Br J Haematol 82:310-316, 1992
3. Tubergen DG, Krailo MD, Meadows AT, et al: Comparison of treatment regimens for pediatric lymphoblastic non-Hodgkin's lymphoma: A Childrens Cancer Group study. J Clin Oncol 13:1368-1376, 1995
4. Amylon MD, Shuster J, Pullen J, et al: Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: A Pediatric Oncology Group study. Leukemia 13:335-342, 1999
5. Reiter A, Schrappe M, Ludwig WD, et al: Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: A BFM group report. Blood 95:416-421, 2000
6. Bergeron C, Gomez F, Pacquement H, et al: Treatment of childhood T lymphoblastic lymphoma (TLL): Results of the SFOP LMT 96. Ann Oncol 13:32, 2002 (abstr 95)
7. Attarbaschi A, Dworzak M, Steiner M, et al: Outcome of children with primary resistant or relapsed non-Hodgkin lymphoma and mature B-cell leukemia after intensive first-line treatment: A population-based analysis of the Austrian Cooperative Study Group. Pediatr Blood Cancer 44:70-76, 2005
8. Won SC, Han JW, Kwon SY, et al: Autologous peripheral blood stem cell transplantation in children with non-Hodgkin's lymphoma: A report from the Korean society of pediatric hematology-oncology. Ann Hematol 85:787-794, 2006
9. Hoelzer D, Gokbuget N, Digel W, et al: Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia. Blood 99:4379-4385, 2002
10. Mitsui T, Mori T, Fujita N, et al: Relapsed or primary refractory childhood lymphoblastic lymphoma: A retrospective analysis of registered cases in Japan. Pediatr Blood Cancer 46:866, 2006 (abstr 96)
11. Sandlund JT, Bowman L, Heslop HE, et al: Intensive chemotherapy with hematopoietic stem-cell support for children with recurrent or refractory NHL. Cytotherapy 4:253-258, 2002
12. Levine JE, Harris RE, Loberiza FR Jr, et al: A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma. Blood 101:2476-2482, 2003
13. Peniket AJ, Ruiz de Elvira MC, Taghipour G, et al: An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: Allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 31:667-678, 2003
14. Bureo E, Ortega JJ, Munoz A, et al: Bone marrow transplantation in 46 pediatric patients with non-Hodgkin's lymphoma: Spanish Working Party for Bone Marrow Transplantation in Children. Bone Marrow Transplant 15:353-359, 1995
15. Burkhardt B, Woessmann W, Zimmermann M, et al: Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous system-negative stage III or IV lymphoblastic lymphoma. J Clin Oncol 24:491-499, 2006
16. Neth O, Seidemann K, Jansen P, et al: Pre-cursor B-cell lymphoblastic lymphoma in childhood and adolescence: Clinical features, treatment, and results in trials NHL-BFM 86 and 90. Med Pediatr Oncol 35:20-27, 2000
17. Möricke A, Reiter A, Zimmermann M, et al: Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: Treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 111:4477-4489, 2008
18. Kaplan EI, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
19. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
20. Kalbfleisch EL, Prentice RL: The Statistical Analysis of Failure Time Data. New York, NY, John Wiley, 1980, pp 163-188
21. Mantel N, Byar DP: Evaluation of response-time data involving transient states: An illustration using heart transplant data. J Am Stat Assoc 69:81-86, 1974
22. von Stackelberg A, Hartmann R, Buhrer C, et al: High-dose compared with intermediate-dose methotrexate in children with a first relapse of acute lymphoblastic leukemia. Blood 111:2573-2580, 2008
23. Cohen MH, Johnson JR, Massie T, et al: Approval summary: Nelarabine for the treatment of T-cell lymphoblastic leukemia/lymphoma. Clin Cancer Res 12:5329-5335, 2006
24. Cooper TM: Role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Ther Clin Risk Manag 3:1135-1141, 2007
25. Jeha S, Gaynon PS, Razzouk BI, et al: Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol 24:1917-1923, 2006
26. Pusill-Wachtsmuth B, Oschlies I, Zimmermann M, et al: Prognostic factors in childhood T-cell lymphoblastic lymphoma treated in the three consecutive NHL-BFM studies. Pediatr Hematol Oncol 25:S4, 2003 (abstr 12)
27. Burkhardt B, Zimmermann M, Oschlies I, et al: The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. Br J Haematol 131:39-49, 2005
28. Campana D, Coustan-Smith E, Sandlund J, et al: A novel approach for staging and minimal residual disease detection in T-cell lymphoblastic lymphoma: A Children's Oncology Group study. Ann Oncol 16:62, 2005 (abstr 89)
29. Burkhardt B, Bruch J, Zimmermann M, et al: Loss of heterozygosity on chromosome 6q14-q24 is associated with poor outcome in children and adolescents with T-cell lymphoblastic lymphoma. Leukemia 20:1422-1429, 2006
30. Burkhardt B, Moericke A, Klapper W, et al: Pediatric precursor T lymphoblastic leukemia and lymphoblastic lymphoma: Differences in the common regions with loss of heterozygosity at chromosome 6q and their prognostic impact. Leuk Lymphoma 49:451-461, 2008
31. Baleydier F, Asnafi V, Decouvelaere A-V, et al: T lymphoblastic lymphoma (T-LL): One or two diseases? Blood 106:789a, 2005 (abstr 2815)
32. Baleydier F, Simon A, Bergeron S, et al: Notch mutations in T-ALL compared to T-LL. Pediatr Blood Cancer 46:867, 2006 (abstr 100)
33. Gallamini A, Hutchings M, Avigdor A, et al: Early interim PET scan in Hodgkin lymphoma: Where do we stand? Leuk Lymphoma 49:659-662, 2008
34. Hutchings M, Loft A, Hansen M, et al: FDGPET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107:52-59, 2006
35. Zhao J, Qiao W, Wang C, et al: Therapeutic evaluation and prognostic value of interim hybrid PET/CT with (18)F-FDG after three to four cycles of chemotherapy in non-Hodgkin's lymphoma. Hematology 12:423-430, 2007